T6580
Triflusal
≥98% (HPLC), powder
别名:
Triflusal, α,α,α-trifluoro-2,4-cresotic acid acetate, 2-(Acetyloxy)-4-(trifluoromethyl)benzoic acid, Drisgen, acetyl-4-trifluoromethylsalicylic acid
SMILES string
FC(F)(F)c1cc(c(cc1)C(=O)O)OC(=O)C
InChI key
RMWVZGDJPAKBDE-UHFFFAOYSA-N
InChI
1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16)
assay
≥98% (HPLC)
form
powder
color
white to off-white
solubility
DMSO: >30 mg/mL
originator
Uriach
storage temp.
2-8°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action.
Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action. It is an irreversible inhibitor of COX-1 inhibiting thromboxane A2, preventing aggregation; it preserves vascular prostacyclin, thus promoting anti-aggregant effect. Triflusal blocks phosphodiesterase leading to an increase in cAMP levels promoting anti-aggregant effect due to inhibition of calcium mobilization.
Features and Benefits
This compound was developed by Uriach. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Yingying Huang et al.
Biomaterials, 31(15), 4382-4391 (2010-03-02)
This study reports on a dual drug-eluting stent (DDES) that has an anti-proliferative and an anti-thrombotic in a biodegradable polymer-coated onto a cobalt-chromium stent. The DDES was prepared by spray coating the bare metal stent with a biodegradable polymer loaded
Teodor Adrian Enache et al.
Combinatorial chemistry & high throughput screening, 13(7), 569-577 (2010-04-21)
The electrochemical behavior of triflusal (TRF) and aspirin (ASA), before and after hydrolysis in water and in alkaline medium using two different electrode surfaces, glassy carbon and boron doped diamond, was study by differential pulse voltammetry over a wide pH
[Resistance to triflusal or an insufficient dose?].
A Lago et al.
Revista de neurologia, 48(8), 443-444 (2009-04-03)
Iñaki Izquierdo et al.
Arzneimittel-Forschung, 60(1), 36-41 (2010-02-27)
Triflusal (CAS 322-79-2) is an antiplatelet agent that irreversibly acetylates cyclooxygenase isoform 1 (COX-1) and therefore inhibits thromboxane biosynthesis. The main metabolite of triflusal, 2-hydroxy-4-trifluoromethyl benzoic acid (HTB), possesses also antiaggregant activity. Recently a new oral 600 mg (10 ml)
Shawn N Whitehead et al.
Brain research, 1366, 246-256 (2010-10-12)
Clinical data has shown that stroke exacerbates dementia in Alzheimer's disease (AD) patients. Previous work, combining rat models of AD and stroke have shown that neuroinflammation may be the common mediator between AD and stroke toxicity. This study examined the
商品
Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持